

27-5 Leui-Dong, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do, Korea 442-270 Tel 82 31 207-2200 Fax 82 31 207-3933



# 510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92.

Date: February 10, 2006

Company and Correspondent making the submission: 1.

·	Company
Name	Dentium Co., Ltd.
Address	27-5 Leui-Dong, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do, Korea 442-270
Phone Fax Contact	+82 31 207-2200 +82 31 207-3933 K. Y. Yoon

### 2. Device:

Proprietary Name - Implantium II Common Name - Dental Implant Classification Name – Endosseous dental implant

Predicate Device: 3.

Implantium, Dentium Co., Ltd., K041368

4. Classifications Names & Citations: 21CFR 872.3640, DZE, Endosseous dental implant, Class2

#### 5. Description:

The Implantium II is a dental fixture made of pure titanium metal intended to be surgically placed in the bone of the upper or lower jaw arches.

The Implantium II is similar to other commercially available products based on the intended use, the technology used, the claims, the material composition employed and performance characteristics. The differences between them are shape and surface. The Implantium II has one-stage and two-stage surgery. The Implantium II has S.L.A. or Anodizing surface while Implantium has S.L.A (Sand-blasted Large grit Acid-etched).

The Implantium II is substantially equivalent in design, function and intended use to



the fixtures of Dentium Co., Ltd. Implantium.

# 6. Indication for use:

Implantium II is intended to be surgically placed in the bone of the upper or lower jaw arches to provide support for prosthetics devices, such as artificial teeth, and to restore the patient's chewing function.

# 7. Review:

Implantium II has the same device characteristics as the predicate device. Material, design and use concept is similar.

## 8. Conclusions:

In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807, and based on the information provided in this premarket notification Dentium Co., Ltd. concludes that Implantium II is safe and effective and substantially equivalent to predicate devices as described herein.



JUN 16 2006

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Dentium Company, Limited C/O Ms. Cathryn N. Cambria President Arkin Consulting Group 5536 Trowbridge Drive Dunwoody, Georgia 30338

Re: K060501

Trade/Device Name: Implantium II Regulation Number: 872.3640

Regulation Name: Endosseous Dental Implant

Regulatory Class: II Product Code: DZE Dated: June 13, 2006 Received: June 14, 2006

## Dear Ms. Cambria:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address. <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

	•
510(k) Number K 406650	
Device Name: Implantium II	
•	le support for prosthetics devices, such as store the patient's chewing function.
	Over-The-Counter Use(Per 21CFR807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE NEEDED)	E – CONTINUE ON ANOTHER PAGE IF
Concurrence of CDRH, Office of	Device Evaluation (ODE)
100.	of Anesthesiology, General Hospital, Control, Dental Devices